Ulipristal, a progesterone receptor antagonist as a contraceptive and for the treatment of uterine fibroids

Curr Opin Investig Drugs. 2007 Oct;8(10):859-66.

Abstract

HRA Pharma, under license from the Research Triangle Institute, is developing ulipristal, a progesterone receptor modulator, for the potential use as a contraceptive and an emergency contraceptive, and for the potential treatment of uterine fibroids. Phase II clinical trials for uterine fibroids and phase III trials for contraception are underway. The drug was expected to be launched in the US and Europe in 2009.

Publication types

  • Review

MeSH terms

  • Animals
  • Contraceptive Agents, Female*
  • Drug Evaluation, Preclinical
  • Female
  • Humans
  • Leiomyoma / drug therapy*
  • Norpregnadienes* / adverse effects
  • Norpregnadienes* / pharmacokinetics
  • Norpregnadienes* / therapeutic use
  • Receptors, Progesterone / antagonists & inhibitors*
  • Receptors, Progesterone / metabolism
  • Structure-Activity Relationship

Substances

  • Contraceptive Agents, Female
  • Norpregnadienes
  • Receptors, Progesterone
  • ulipristal